Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.
Cureus September 2026 Robert B Raffa
An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These...